focus -WSS

focus

author：hotspot 2025-09-29 02:42:06 Page View：57423

Joaquin Duato -- health policy coverage from STAT — Johnson & Johnson CEO Joaquin Duato MICHAEL BUHOLZER/AFP via Getty Images

WASHINGTON — Merck CEO Robert Davis and Johnson & Johnson CEO Joaquin Duato have agreed to voluntarily testify before the Senate health committee, avoiding a threatened subpoena, the committee announced Friday.

The decision by the executives came after a public pressure campaign by Sanders to get the two executives and Bristol Myers Squibb CEO Chris Boerner to testify about why prices for their drugs are higher in the United States than in other countries. Sanders had scheduled a vote to subpoena the Merck and Johnson & Johnson CEOs on Jan. 31, but canceled it on Friday.

“The use of a subpoena was clearly a last resort and I’m delighted that these CEOs will be coming into our committee voluntarily,” Sanders said in a written statement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At ASCO, pharma leaders speak of advances in 'smart bomb' drugs
Next article： Wildfire smoke exposes gaps in outdoor worker protections

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

Shifting the focus from loneliness to social health

AdobeIt’sbeenoneyearsincetheU.S.surgeongeneralissuedanationalwarningaboutanepidemicofloneliness.Othe

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

New case study details death in closely watched Alzhiemer's trial

AbrainaffectedbyAlzheimer'sdisease,attheMuseumofNeuroanatomyattheUniversityatBuffalo.DavidDuprey/API

focus

leisure time

Wikipedia

New case study details death in closely watched Alzhiemer's trial